Anavex Presents Data on Potential Dual Utility of ANAVEX 2-73 in Both Amyloid and Tau Pathology

Hoboken, NJ — July 25, 2011 — Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) is pleased to provide a summary of the first of two poster presentations at the Alzheimer’s Association International Conference (AAIC) held in Paris, entitled “The novel aminotetrahydrofuran derivative ANAVEX 2-73 attenuated GSK-3beta and Tau hyperphosphorylation in a nontransgenic Alzheimer’s disease model…